Human “Intelligence” in the form of qualified human resources has been the key component in driving the growth of the pharma industry domains. The industry has been a “blessed” industry with a as talent pool in the current Century. This is on account of reputed institutions offering a range of pharmacy courses at graduate & …

Continue reading “Impact and role of AI in pharmaceutical industry”

INTERNATIONAL trade declined heavily in 2020 across the globe but recovered sharply in 2021. In the current scenario, trade flows across goods and services are stable. However, trade partners across the globe are highly diverse which creates tremendous pressure on some sectors and supply chains. The impact of Covid 19 in a single year was identical to …

Continue reading “Emerging trends in pharmaceutical and chemicals”

Article published in the 26 Jan 2023 edition of 22nd Anniversary special of Chronicle Pharmabiz. USFDA conducts inspections across the world in more than 100 countries in areas of Biologics, Devices, Drugs, Food/Costetics, Tobacco and veterinary with a yearly average (2009-2022) of 18000. How ever, USFDA inspections had slowed during the pandemic due to travel …

Continue reading “USFDA Inspections and Impact on Indian Pharma”

Introduction and Overview Germany is ranked as a leader in clinical trials conducted in Europe and ranked as among top 5 in the world. Clinical trial data quality is at par with the US, costs are up to 50 percent lower in Germany. The country’s key competitive advantage lies in the combination of lower costs …

Continue reading “Clinical Research in Germany- A Contemporary perspective”

India lab and chemicals markets: the story post 2010 The world chemicals market in the period 2014-2015 has witnessed significant changes. The market has seen very high growth paths in the years 2001-2009. Post 2010, the sce- nario has taken shift towards emerging markets. The devel- oped world particularly Europe which accounts for the largest …

Continue reading “India lab and chemicals markets: the story post 2010”

THE Indian active pharmaceutical industry is the largest component of the Indian pharmaceuticals sector in terms of both value and volume according to report by IBEF published in January 2016.The growth drivers for the Indian API have been two- fold. The primary demand for is catering to the domestic market where the same are used …

Continue reading “Emerging trends in API for DMF filings in the US”

Innovative and intelligent pharmaceutical packaging Nonadherence or lack of patient compliance to much needed med-icines is on the rise.One of the very common reasons is forgetting to take the medicine or stop taking their medicine earlier than instructed. Many of the reasons for non -compliance are very complex and one of the reasons is lack …

Continue reading “Innovative and intelligent pharmaceutical packaging”

Off patent generic drugs manufactured in India are the key sources of cure for the diseases affecting the populations of the developed world. However, it needs to be seen if the western world is getting enough of those medicines for curing those diseases at the appropriate time intervals. The off patent drugs which any pharmaceutical …

Continue reading “Drugs short supply in US offers huge opportunity for Indian pharma industry”

The Indian pharmaceutical industry is the largest supplier of cost effective generic medicines to the developed world. With the widest range of medicines available for exports and with the availability of the largest number of approved pharmaceutical manufacturing facilities, India is all set to become the leader of pharmaceutical exports to the world. According to …

Continue reading “Indian pharmaceutical exports: The growth story”

The blood pumping mechanism of the body, ie the heart, is one of the most important organs in the human body. This is one of the organs which experiences extensive stress. The stress which the human heart goes through is because of both internal and external factors. Some of the factors could be genetic in …

Continue reading “The cardio factor: An insight into heart disease”

Patent expiration: The generic factor Key companies like Amgen, Pfizer, Roche, BMS and Novartis have their bestselling patented brands used for curing life threatening diseases facing patent expirations. The question then arises as to what these companies must do in order to ‘save’ their brands which have acceptability among the payers in the US and …

Continue reading “Future of branded drugs in a generic world”

Where there is sugar, there are ants and ants are considered to be the most diligent living forms. But when it comes to the sugar disease, ie, diabetes, it is highly challenging to achieve the desired results in clinical trials but also the right investigators and funding for those trials too. Needless to say, the …

Continue reading “Diabetes cure: An insight into research post exit of glitazones”

The popular saying ‘United we stand, divided we fall’ is a popular phrase which signifies various aspects of coming together for a common goal or a purpose. This has been a recurring feature for the global pharmaceutical industry as well. As pressures on drug manufacturing, research and development and regulatory aspects have been on the …

Continue reading “Whats driving mergers and acquisitions in pharma industry?”

Funding is difficult to come by for pain killer research since challenges of data collection for clinical trials is high as compared to any other therapeutic area. The dimension of physical pain for human beings range from a minor back pain to low back pain, back pain, osteoarthritis/rheumatoid arthritis, joint pain, muscle pain, neuropathic pain, …

Continue reading “Is global pharma industry investing enough in pain killer research?”

CNS disorders rake in more than $ 80 billion a year for the pharma industry, however higher failure rates in clinical trials are forcing big companies to cut down their spend on CNS drug R&D. The most complicated area of clinical research post 2013 is the central nervous system (CNS). Big pharmaceutical companies are keen …

Continue reading “CNS drug research: A dilemma for big pharma companies”

India has long been the focus of the world for clinical research particularly since 2005. The market has been always every investors’ focus of attention on account of India’s massive population, large patient pool from various races, cost arbitrage, wide spectrum of diseases and availability of English speaking technical expertise in rising numbers. The Indian …

Continue reading “India clinical research market: Rebounding from post-2011 slump”

US FDA import warning due to data integrity problems IPCA Laboratories’ Ratlam unit received an import alert from the US drug regulator on 22 January 2015 for not complying with good manufacturing practices requirements of the US FDA. IPCA Laboratories is a leading manufacturer of pharmaceutical medicines producing greater than 350 formulations and 80 APIs …

Continue reading “US FDA import warning due to data integrity problems”